Simcere Pharmaceutical Group signed an exclusive global licensing agreement with Roche for SIM0660, a CD79a/CD19/CD3 trispecific antibody, securing a $75 million upfront payment and up to $1.455 billion in milestone payments plus tiered double-digit royalties. This marks the second asset from Simcere's TCE technology platform to achieve out-licensing, confirming the platform's global competitiveness.
Simcere Pharmaceutical Group (2096.HK) signed an exclusive global licensing agreement with Roche for SIM0660, a CD79a/CD19/CD3 trispecific antibody, securing a $75 million upfront payment and up to $1.455 billion in milestone payments plus tiered double-digit royalties, the Chinese drugmaker said Tuesday.
"This licensing deal marks the second asset from the group's tumor T-cell engager technology platform to achieve out-licensing, further confirming the innovation strength and global competitive advantages of the platform," Simcere said in a filing to the Hong Kong Stock Exchange.
SIM0660, developed on Simcere's TCE poly-specific antibody platform, is designed to induce T cell-mediated cytotoxicity against B-cell malignancies while limiting cytokine release. The dual targeting of CD79a and CD19 aims to treat newly diagnosed and relapsed or refractory B-cell cancers, including patients who have previously received CD20- or CD19-directed therapies. A Simcere spokesperson told Reuters the product is at the preclinical stage.
Under the agreement, Roche obtains exclusive global rights to develop, manufacture and commercialize SIM0660. Beyond oncology, the candidate also shows potential in B-cell-mediated autoimmune diseases where selective depletion of pathogenic B cells could provide clinical benefit.
The deal with Roche, one of the world's largest pharmaceutical companies, provides a significant cash infusion and validates Simcere's TCE platform on a global stage. The $75 million upfront payment offers immediate liquidity, while the milestone structure represents substantial long-term upside tied to clinical and commercial progress. Simcere shares traded at HK$11.00, down 0.991 percent, with a market capitalization of HK$29.02 billion. The most recent analyst rating on the stock is a Buy with a HK$16.30 price target.
The licensing agreement strengthens Simcere's position in oncology and potential autoimmune indications, creating a revenue stream that may support further research and development investment. Investors will watch for Roche's clinical trial timelines for SIM0660, which the Swiss drugmaker has not yet disclosed, as the next catalyst for the stock.
This article is for informational purposes only and does not constitute investment advice.
